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Background: Lipids are stored within cells in lipid droplets (LDs). They consist of a core of neutral lipids surrounded
by a monolayer of phospholipids, predominantly phosphatidylcholine (PC). LDs are very dynamic and can rapidly
change in size upon lipid uptake or release. These dynamics require a fast adaptation of LD surface. We have
recently shown that two Lands cycle PC synthesizing enyzmes, LPCAT1 and LPCAT2 can localize to the LD surface.
Results: Here, we show that knock-down of both enzymes leads to an increase in LD size without changes in the
total amount of neutral lipids, while interference with the de-novo Kennedy pathway PC biosynthesis is associated
with changes in triacylglyceride synthesis. We show that function of LPCAT1 and 2 is conserved in Drosophila
melanogaster by the ortholog CG32699. Furthermore we demonstrate that modulation of the LD pool by LPCAT1
influences the release of lipoprotein from liver cells.
Conclusion: Activity of the Kennedy pathway regulates the balance between phospholipids and neutral lipids,
while the Lands cycle regulates lipid droplet size by regulating surface availability and influencing surface to
volume ratio. Differences in lipid droplet size may account for differences in lipid dynamics and be relevant to
understand lipid overload diseases.
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Lipids are important components of cells, with a func-
tion in cellular structure, regulation, signaling and as en-
ergy source, in particular neutral lipids. The cellular
location of storage of neutral lipid is the lipid droplet
(LD). LDs consist of a core of neutral lipids that is sur-
rounded by a monolayer of phospholipids, mainly phos-
phatidylcholine [1-3]. Different proteins are associated
with the LDs, including several enzymes of lipid metab-
olism [4-15].
Many metabolic disorders like diabetes and cardiovas-
cular diseases are associated with defects in lipid* Correspondence: cthiele@uni-bonn.de
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unless otherwise stated.metabolism and derive from additive defects in different
pathways, often described as metabolic syndrome that can
gradually progress into more severe diseases. The first step
is usually the excess storage of lipids within different body
tissues resulting in the development of obesity [16-19].
Therefore, it is crucial to understand how the storage of
lipids is regulated under normal conditions.
Lipids are in a constant flux and are continuously con-
verted into each other. Within cells they can move within
membranes and between different cellular compartments.
Furthermore, lipids are exchanged between different tis-
sues. Extracellularly, the bulk of lipids is transported in li-
poproteins. These lipoproteins are soluble complexes of
proteins (apolipoproteins) and lipids that are transported
in the circulation of vertebrates and insects and that are
synthesized in the liver and intestine. They are classifiedntral. This is an Open Access article distributed under the terms of the Creative
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density (LDL) and high density (HDL) lipoproteins based
on their apolipoprotein component and their density,
which is determined by the lipid composition [20]. The
major neutral lipid, triacylglycerol (TAG), is secreted from
the liver and intestine in apolipoproteinB (apoB) contain-
ing lipoproteins (CM and VLDL). In contrast to other
apolipoproteins, apoB is not exchangeable between lipo-
proteins and resides in the plasma in a lipid-associated
form only. While VLDL and CM contain apoE, apoC and
apoB, LDL harbors exclusively apoB. In the absence of
loaded lipids apoB cannot be secreted and is rapidly de-
graded [21,22]. The TAG secreted as CM and VLDL
mainly derives from TAG stored in cytosolic LDs [23].
Depending on cell type, nutritional status and develop-
mental state the LD pool can vary in droplet number,
size and localization within short time scales [24]. The
growth of LDs and the incorporation of FAs into TAG is
a fast event, typically taking just a few minutes [25,26].
Once formed, lipid droplets can fuse with each other
[27] or transfer material by a slow coalescence event
[28-30]. Chronic stimulation of lipolysis in adipocytes re-
sults in a fragmentation of large LDs into small LDs,
which are dispersed throughout the cell [4,31-33]. These
rapid changes of the LD core require a similarly rapid
increase or decrease of the LD surface or an adaptation
of the surface to volume ratio.
The major phospholipid of the LD surface, phosphatidyl-
choline, can be synthesized by three different pathways: the
de-novo pathway, which is also known as Kennedy path-
way, the Lands cycle and the phosphatidylethanolamine
methyl transferase (PEMT) pathway, which is restricted to
liver cells [34]. In the Kennedy pathway, phosphocholine is
activated with cytidine triphosphate (CTP) and transferred
to diacylglyceride (DAG) to form PC. These reactions are
catalyzed by the cytoplasmic CTP:phosphocholine cytidy-
lyltransferase (CT alpha) and the membrane-embedded
cholinephosphotransferase or choline/ethanolamine phos-
photransferase (CEPT1/CPT1) [35]. In the Lands cycle
phospholipase A2 (PLA2) removes fatty acids at the sn-2
position of PC, which results in the formation of lysopho-
sphatidylcholine (LPC). This can be used in a reverse reac-
tion, the addition of a fatty acid at the sn-2 position, to
yield PC. This re-acylation is catalyzed by lysophosphati-
dylcholine acyltransferases (LPCATs) [36]. Recently, four
LPCATs were cloned and characterized [37-42]. They are
all reported to localize to the ER compartment. Due to
their structure they divide into two subgroups with
LPCAT1 and LPCAT2 in one and LPCAT3 and LPCAT4
in the other group. LPCAT1 is reported to function in lung
surfactant production, while LPCAT2 seems to be import-
ant in inflammatory reactions.
We have recently shown that diacylglycerol acyltrans-
ferase 2 (DGAT2) can localize to the surface of LDs andis active in synthesizing locally TAG stored in the core
of LDs [25]. Furthermore, we have also shown that two
enzymes of the Lands cycle, LPCAT1 and LPCAT2, can
localize to the surface of LDs and that they can
synthesize PC directly at the LD [43].
Here, we show that these proteins are important for the
morphology of the cellular LD pool in different mamma-
lian cell types and Drosophila melanogaster. We demon-
strate that interference with both cellular PC synthesis
pathways results in an increase in LD size, but due to dif-
ferent mechanisms. We identified the LPCAT1/2 ortholog
in Drosophila melanogaster and demonstrate its LPCAT
activity. Additionally, we show that interference with
LPCAT1 influences lipoprotein particle secretion from
hepatoma cells.
Results
Knockdown of LPCAT1 and LPCAT2 increases LD size
Since both LPCAT1 and LPCAT2 are present and active
at the surface of LDs, we investigated their importance for
the cellular LD pool. If local production of PC by LPCAT1
and LPCAT2 is functionally important for the LD mono-
layer, manipulation of LPCAT activity may result in a
phenotypic alteration of cellular LD pools. Therefore, we
performed siRNA-mediated gene silencing of the LPCATs
followed by microscopic imaging of LDs, quantification of
LD size and number and further characterization of the
phenotype. A double knockdown (KD) of LPCAT1 and
LPCAT2 by means of two different specific siRNAs target-
ing LPCAT1 and LPCAT2 lead to a reduction of both pro-
teins in A431 cells (Figure 1A). This reduction resulted in
a significant increase in the mean size of LDs, expressed
as the cross-sectional area (Figure 1B and C) and a slightly
reduced number of LDs (Figure 1D). Since double KDs
are difficult and phenotypes are weak due to mutual
compensation by the isoenzymes, we also analyzed the
human hepatoma cell line HuH7, which expresses
LPCAT3 [41] and LPCAT1, but no LPCAT2 [43].
Knockdown of LPCAT1 in HuH7 cells with two differ-
ent siRNA sequences resulted in a decreased LPCAT ac-
tivity in whole cell lysates (Figure 2A, upper row) and in
a decrease in LPCAT1 protein down to about 10% of
control (Figure 2A, middle row). Phenotypically, this
KD resulted in the appearance of larger LDs (Figure 2B).
A quantification of the microscopic images revealed a
significant increase in the mean LD size upon LPCAT1
KD (Figure 2C). This increase is due to a shift in the LD
size distribution from small LDs (50-300 nm2) to larger
LDs (400 nm2- >1 μm2) (Figure 2D). This increase in
size is paralleled by a significant decrease in number of
LDs (Figure 2E). The results show that a reduction of
LPCAT1 and LPCAT2 leads to a shift of the cellular LD
sizes to larger LDs accompanied by simultaneous de-
crease in number of LDs in different cell types.
Figure 1 (See legend on next page.)
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Figure 1 Silencing of LPCAT1 and LPCAT2 by siRNA leads to enlarged lipid droplets in A431 cells. A) A431 cells were either left untreated
(untreated, wt), mock transfected (mock), transfected with control siRNA (eg5 as transfection control, leads to cell death, or scrambled#5 + #6 as
non-targeting siRNAs) or the four possible combinations of two sequences each against LPCAT1 or LPCAT2 as indicated. After 48 h cells were lysed
and subjected to SDS-PAGE/Western blotting for LPCAT1, LPCAT2 and glycerol-3-phosphate dehydrogenase (GAPDH, as a load control). B) Confocal
images of controls and LPCAT1/LPCAT2 double-knock-downs as described in panel A. Nuclei (blue), LDs (green), scalebar = 10 μm. C) Confocal images
as described in panel B were quantified with Image J for LD size distribution as described in Methods. Data are mean LD size ± StdDev, calculated
from>50 individual cells in 3 independent experiments. Significances relative to non-targeting siRNAs were calculated by unpaired two-sided T-test
analysis (*** p≤ 0.001, ** p≤ 0.01, * p≤ 0.05). D) Confocal image as described in panel B were quantified with ImageJ. Data show mean lipid droplet
number per frame, corrected for variations in cell density, calculated from>50 individual cells in 3 independent experiments. Control: scrambled#5 +
#6, LPCAT siRNA: average of all siRNA treatments. Significance was calculated by unpaired two-sided T-test analysis (*** p≤ 0.001).
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particle secretion
HuH7 cells synthesize and secrete apoB containing
VLDL particles [21,44] with a similar density as LDL
particles (Additional file 1: Figure S1), whose assembly
requires the long-chain acyl-CoA synthetase ACSL3
[45]. This protein activates fatty acids for subsequent in-
corporation into PC and localizes to LDs [46], suggest-
ing that it functions together with LPCAT1 in PC
synthesis at LDs. Earlier studies suggested that secretion
of VLDL would depend on mobilization of TAG from
LDs [23], which might be slower when small LDs are re-
placed by larger LDs with a smaller surface to volume
ratio. Given these close connections between hepatic
TAG and PC metabolism, we hypothesized that LPCAT1
activity might also influence lipoprotein assembly and
secretion. To address this issue, we monitored the se-
cretion of lipoprotein particles from HuH7 cells by
measuring the amount of secreted apolipoprotein B
(apoB). Knockdown of LPCAT1 with two distinct siR-
NAs resulted in a significant reduction of apoB secre-
tion and a decrease in secretion of radiolabeled lipids
(Figure 2F).
LD size increase occurs without changes in the neutral
lipid pool
An increase of LD size can result from an overall in-
creased storage of neutral lipids, particularly TAG, or
from a morphological rearrangement of the LD pool at
constant TAG amounts. Neither A431 (Figure 3A) nor
HuH7 (Figure 3C) cells showed a difference in incorpor-
ation of alkyne-labeled oleate into TAG relative to in-
corporation into PC between control siRNA-treated
cells and cells treated with LPCAT1- and LPCAT2-specific
siRNA. Additionally, also the amount of other major lipid
species remained unchanged independent of the siRNA
treatment in both cell lines, A431 (Figure 3B) and HuH7
(Figure 3D). The results suggest that the mechanism for
the increase in LD size results from an adjustment of the
surface to volume ratio rather than the formation of more
neutral lipids.LD size increase by inhibition of the de-novo PC synthesis
pathway is connected to changes in neutral lipid content
It was reported that interference with the de-novo PC
pathway also results in increased LD size in S2 cells
[47,48]. Furthermore, the inhibition of this pathway leads
to a switch in lipid metabolism from the formation of
PC towards the formation of TAG [49]. In A431 cells,
we observed an increase in the size of LDs (Figure 4A,B)
upon knockdown of CTalpha mRNA (Figure 4C) along
with a decrease of the ratio of PC to TAG biosynthesis
(Figure 4D). Steady state lipid pool size, analyzed by mass
spectrometry, showed a non-significant tendency towards
increased TAG and CE and a significant reduction of
ether-linked PC (Figure 4E) upon CTalpha knock-down.
LPCAT3 and LPCAT4 do not influence the cellular LD pool
Besides the homologous LPCAT1 and LPCAT2 two other
proteins with LPCAT activity were identified and named
LPCAT3 and LPCAT4 [41,50]. These proteins belong to a
different family of proteins and are multispan transmem-
brane proteins structurally related to ACAT (Acyl-CoA
Cholesterol Acyltransferase) proteins. Especially, the ubi-
quitous LPCAT3 was reported to be the main LPCAT in
liver cells [41]. Though these proteins were not identified
on LDs, but were reported to localize to the ER compart-
ment, we investigated whether a single or double knock-
down of these proteins has an effect on the LD pool. In
A431 cells, no effect on the mean LD size (Figure 5A) was
observed upon knock-down of LPCAT3 mRNA, LPCAT4
mRNA or combinations thereof (Figure 5B) Consistent
with the fact that neither LPCAT3 nor LPCAT4 localize
to LDs, LPCAT activities of LD preparations were un-
affected by the knock-downs (Figure 5C), while total
cell lysates showed significantly reduced LPCAT activities
(Figure 5D). This indicates that only LPCATs with the
ability to localize to LDs influence the LD size.
The Drosophila melanogaster LPCAT1/2 ortholog CG32699
has LPCAT activity, localizes to LDs and regulates LD size
The ability to form LDs is conserved from yeast to mam-
mals, and orthologs of many mammalian LD proteins and
Figure 2 (See legend on next page.)
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Figure 2 Silencing of LPCAT1 by siRNA leads to enlarged lipid droplets and reduced lipoprotein secretion in HuH7 cells. A) HuH7 cells
were either left untreated (untreated, wt), mock transfected (mock), transfected with control siRNA (scrambled#5 or scrambled#6 as non-targeting
siRNAs) or the two different siRNA sequences against LPCAT1 as indicated. After 72 h cells were subjected to a LPCAT activity assay or Western
blotting (WB) for LPCAT1 using GAPDH, as load control. B) Confocal images of controls and LPCAT1 knock-downs as described in panel A. Nuclei
(blue), LDs (green), scale bar = 10 μm C + D) Confocal images as described in panel B were quantified for LD size distribution as described in
Methods. Data represented mean LD size ± StdDev, calculated from > 50 individual cells in 3 independent experiments. Significances were calculated
by unpaired two-sided T-test analysis relative to non-targeting siRNA (scrambled#5) (*** p ≤ 0.001). For analysis of LD size distribution (panel D), LDs
were grouped into size classes, and the distribution displayed as percentage of total LDs per size class. Controls (black, light and dark grey and white),
siRNAs against LPCAT1 (red, blue). E) Confocal images as described in panel B were quantified with Image J. Data show mean lipid droplet number
per frame, corrected for variations in cell density, calculated from >50 individual cells in 3 independent experiments. Control: average of scrambled#5
and scrambled#6, LPCAT siRNA: average of both siRNA treatments. Significance was calculated by unpaired two-sided T-test analysis (*** p ≤ 0.001).
F) HuH7 cells were transfected with non-targeting siRNA (control) or different siRNA sequences targeting LPCAT1 as indicated. ApoB secretion was
measured by ELISA (dark grey, data represent mean ± StdDev, n = 4) or by Western blotting (light grey, data represent mean ± StdDev, n = 5). [3H]lipid
secretion after labeling with 1 μCi [3H]oleate was calculated as % of total radioactivity recovered (supernatant + cells) and normalized to control. Data
represent mean ± StdDev, n = 4. p-Values were obtained by unpaired T-test relative to the respective control (** p ≤ 0.01, * p ≤ 0.05).
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model organisms like Drosophila melanogaster [47,51-54].
In Drosophila, cutting-edge genetic technologies can be
combined with immunohistochemistry, cell biology and
biochemistry approaches. Furthermore, manipulations of
the metabolism can be achieved by feeding specific diets
that contain particular metabolites (e.g. labeled lipids) or
chemical inhibitors [55-57] and the analysis of metabolite/
lipid fluxes between tissues can be studied. Many func-
tions of the mammalian liver and adipose tissue are exe-
cuted in the insects fat body, an organ that is particularly
pronounced in the late larval state [58].
In order to test whether the influence of the LD local-
izing LPCAT1 and LPCAT2 on the cellular LD pool is
conserved in evolution, we investigated their function on
the organismic level. LPCAT1 and LPCAT2 have one
predicted ortholog in Drosophila melanogaster, which is
annotated as CG32699 and is predicted to be a LPC
acyltransferase. GFP-conjugated CG32699 in oleate-
supplemented S2 cells showed colocalization with LDs
(Figure 6A). Three different CG32699-specific RNAi
Drosophila strains showed reduced levels of CG32699
mRNA (Figure 6B, inset). By DIC microscopy on isolated
fat bodies of L3 larvae, we observed enlarged LDs in the
fat body of RNAi strains (Figure 6B). Quantification of
DIC images from RNAi strains show a reduction in the
number of LDs (Figure 6C) while the size of LDs is in-
creased (Figure 6D), similar as was seen for mammalian
cells in culture. LPCAT activity assays on L3 larvae
showed that LPCAT activity was decreased in the RNAi
strains, indicating that this protein indeed has LPCAT
activity (Figure 6E). These results show that the influ-
ence of LPCAT1/2 on the cellular LD pool is a general
property of these proteins beyond cell types and species.
Discussion
To rationalize the different effects of the above knockdowns,
it is necessary to recapitulate the different isoenzymesand pathways that produce the main components of
LDs, i.e. TAG and PC. In most eukaryotes, TAG is pro-
duced by DGAT1 and DGAT2. While DGAT1 is a mul-
tispan protein localizing to the ER [59], DGAT2 has a
hairpin structure and localizes to both the ER and LDs
[25,60,61]. A similar, but more complex situation exists
for the synthesis of PC. The formation of CDP-choline
by CT alpha, the rate limiting step of the PC de-novo
Kennedy pathway, localizes to LDs and ER [15], but the
actual synthesis of PC by CEPT1 and CPT1 is confined
to the ER and Golgi [62] and not found on LDs [43].
The alternative LPCAT pathway, which forms PC from
LPC and acyl-CoA (Lands cycle), has at least four isoen-
zymes, two of which, i.e. LPCAT3/4, are exclusively on
the ER [41,63], while LPCAT1/2 again localize to ER
and LDs [43,64]. Direct regulatory interactions between
the pathways exist, e.g. LPCAT1 promotes the ubiquitin-
mediated degradation of CPT1 [65]. Analogous to DGAT1,
LPCAT3/4 are multispan proteins [41,63] while LPCAT1/2
have a hairpin structure like DGAT2 [43]. Some tissues,
particularly liver, and organisms such as bakers yeast have
in addition the PEMT pathway to convert PE to PC by
methylation [66], which will not be discussed in more
detail here.
Essentially, our data now show that reduction of
LPCAT1/2 results in unchanged balance between PC
and TAG synthesis, along with a remodeling of LD
morphology towards larger LDs, while reduction of the
de novo pathway enzyme CT alpha changes the balance
between PC and TAG synthesis towards the latter,
accompanied by larger LDs and higher TAG content. Re-
duction of ER-localized LPCAT3/4 apparently does not in-
fluence neutral lipid storage. Also, knockdown of LPCAT1
decreases lipoprotein secretion by hepatoma cells.
These observations are consistent with the following
scenario: De-novo PC synthesis by the Kennedy pathway
occurs mostly at the ER and depends on the availability
of choline and its activation to CDP-choline by CT alpha.
Figure 3 Increase in LD size upon LPCAT1/2 knock-down is independent of neutral lipid synthesis and accumulation. A) A431 cells were
transfected with siRNA as described in Figure 1A. Seventy hours after siRNA transfection growth medium was exchanged to medium containing
10% delipidated FCS and 50 μM alkyne-oleate. After two hours cells were washed and lipids extracted. Extracts were subjected to quantitative
click-analysis for the ratio of incorporation of alkyne fatty acid into TAG and PC. Data are mean ± StdDev, n = 3. Significances were calculated by
unpaired two-sided T-test analysis relative to non-targeting siRNA (scrambled#5 + #6) and were found to be insignificant. B) A431 cells were
transfected as described in Figure 1A. After 48 h, total lipid extracts were analyzed by mass spectrometry in duplicate samples, and species
abundances were normalized to the corresponding internal standard. The molar contents of each species of the same class were summed up
and normalized to the total content of all detectable lipids. C) HuH7 cells were transfected with siRNA as described in Figure 2A. Seventy hours
after siRNA transfection as indicated, growth medium was exchanged to medium containing 10% delipidated FCS and 50 μM alkyne-oleate. After
two hours, cells were washed, lipids extracted and extracts were subjected to quantitative click-analysis as in panel A. Data are mean ± StdDev,
n = 3. Significances were calculated compared to non-targeting siRNAs (scrambled#5) and were found to be insignificant. D) HuH7 cells were
transfected as described in Figure 2A. After 72 h, total lipid extracts were analyzed by mass spectrometry in duplicate samples. Species abundances
were normalized as described for panel B.
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choline is lacking, low PC synthesis capacity is balanced
by increased synthesis and storage of neutral lipid [67].
The small extra amount of LD surface PC that is necessaryto store the increased amounts of TAG [68] is likely re-
cruited from other cellular membranes. Since cell growth
and division requires synthesis of PC [69,70], the stored
TAG can provide the precursors for PC synthesis once
Figure 4 (See legend on next page.)
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Figure 4 Inhibition of de-novo PC synthesis results in increased LD size and TAG synthesis. A431 cells were left untreated (untreated),
treated with transfection reagent (mock) or transfected with a non-targeting stealth siRNAs (non-targ.) or three different stealth siRNAs against
CT alpha (siRNA1-siRNA3) for 72 h. A) Representative confocal images, stained with DAPI (blue) and LD540 (orange). Bar, 10 μm. B) Images were
analyzed for LD size as described in Methods. Data are mean LD size ± StdDev, calculated from > 50 individual cells in 3 independent experiments.
Significances were calculated by unpaired two-sided T-test analysis relative to non-targeting control (non-targ.) (*** p ≤ 0.001, ** p ≤ 0.01).
C) Amount of CT alpha mRNA left after CTalpha knock-down relative to non targeting control, measured by real-time PCR. Standard deviations and
significances were calculated by unpaired T-test analysis from 3 different experiments (*** p ≤ 0.001). D) Seventy hours after siRNA transfection as
indicated, growth medium was exchanged to medium containing 10% delipidated FCS and 50 μM alkyne-oleate. After two hours cells were washed
and lipids extracted and analyzed for alkyne labeled TAG and PC. Data are mean ± StdDev, n = 3. Significances were calculated by unpaired two-sided
T-test analysis relative to non-targeting control (non-targ.) (*** p ≤ 0.001, * p ≤ 0.05). E) A431 cells were transfected as described for panel A. After 72 h,
total lipid extracts were analyzed by mass spectrometry in triplicate samples. Species abundances were normalized to the corresponding internal
standard. Species of each class were summed up and normalized to total detectable lipids. Significances for TAG, CE and PC O- were calculated
by unpaired two-sided T-test analysis relative to non-targeting control (### p ≤ 0.001, # p ≤ 0.05) and relative to mock transfection (*** p ≤ 0.001).
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synthesis of PC is supported by the activation of CT alpha
upon recruitment to LDs (64). The de-novo synthetic PC
will be processed by the Lands cycle enzymes LPCAT1-4.
Amongst those, LPCAT1/2 influence the LD size but not
the amount of synthesized PC or TAG. The increase of
LD size upon decrease of LPCAT1/2 activity suggests that
these enzymes are either involved in the recruitment of
PC to the growing LDs by vectorial acylation of the sol-
uble precursor LPC or that their effect on PC species
composition reduces the tendency of LDs to coalesce.
The fact that reduction of LPCAT3/4 does not result
in the same phenotype underlines the importance of
compartmentalization. The different physical properties
of bilayer and monolayer membranes lead to separation of
these isoenzymes with polytopic and monotopic mode of
membranes insertion. This allows compartmentalization
of synthesis and maintenance of separate pools with differ-
ent fate, but makes cells susceptible towards defects in
one of the enzymes.
The complex organization of lipid metabolism is also
illustrated by the role of LPCAT activity in lipoprotein
secretion. Knockdown of LPCAT1 reduced lipoprotein
secretion but had a very small effect on cellular lipid
composition (Figure 3D). Previous findings suggested
that lipidation of VLDL requires breakdown of stored
TAG and transfer of released fatty acids from LDs to
VLDL [23] possibly via ER-luminal LDs [71]. Therefore,
it is possible that LPCAT1 influences lipid secretion by
direct supply of PC for the formation of lipoprotein par-
ticles in the ER, although it appears unlikely that re-
duced LPCAT1 leads to a shortage of PC at the ER,
where the PC de-novo synthesis pathway operates. Re-
duced VLDL secretion in HuH7 cells was also observed
upon knock-down of ACSL3, and could be rescued by
supplementation with PC [45]. Since both ACSL3 [46]
and LPCAT1 localize to LDs, this supports the idea
that ACSL3 supplies acyl-CoAs to LPCAT1 to generate
PC on the LD surface, where about 50% of cellular
LPCAT1 are found in HuH7 cells. The influence on lipidsecretion may then arise from a changed lipid mobilization
from LDs, where an increase in LD surface seems to be
connected to increased lipolysis [31-33]. It is possible that
the activity of LPCAT1 is needed to provide surface area
for the LD attachment of lipid degrading and transferring
proteins. By this way interference with LPCAT1 would
slow down lipid secretion without interfering with the ac-
tual secretion process.
The phenotype of LPCAT1/2 depletion is identical in
both, cultured cells and in the fat body of the multicellu-
lar organism Drosophila melanogaster. Since it is re-
ported that many mammalian proteins and signalling
pathways in lipid metabolism are conserved in Drosophila
melanogaster (Brummer-ATGL, CG1882-CGI-58, CG11055-
HSL, LSDs-PAT) [72] the similar phenotype in the
mammalian cell lines and Drosophila fat body suggest a
conserved mechanisms of LD surface control. As this sin-
gle ortholog behaves similar to the mammalian proteins, it
will be easier accessible for functional studies. In particular
with the Drosophila model there is a multicellular model
available, in which the importance of the protein in devel-
opment or in lipid fluxes between tissues can be studied
by creating a real knock-out fly.
Conclusion
LDs are dynamic organelles that grow or shrink within
minutes during periods of high FA availability or upon
stimulation of lipolysis. We showed that for the growth of
LDs the necessary enzymatic activities, namely DGAT2
for TAG production and LPCAT1 and LPCAT2 for sur-
face PC production, are directly located to the surface of
the LD. In line with the idea of local adjustment of LDs
to growth and shrinkage, we showed that reduction of
surface PC producing enzymes LPCAT1 and LPCAT2 in-
fluences lipid packaging. The restriction of LD PC synthe-
sizing enzymes leads to increased LD size paralleled by
reduced LD number, unchanged cellular neutral lipid con-
tent and reduced cellular lipid release. Our observations
also emphasize the importance of isoenzymes, their differ-
ent cellular localization and parallel synthesis pathways.
Figure 5 LD size is unaffected by knock-down of LPCAT3 and LPCAT4. A) A431 cells were either left untreated, mock transfected (mock) or
transfected with a non-targeting stealth siRNAs (non-targ.) or with the two different stealth siRNA sequences against LPCAT3 (siRNA3-1, siRNA3-2)
or LPCAT4 (siRNA4-1, siRNA4-2) or combinations thereof as indicated. After 72 h incubation cells were fixed, stained with DAPI and LD540 and
imaged. LD size was quantified with ImageJ. Standard deviations and significances were calculated from 3 experiments by unpaired T-test analysis
compared to non-targeting control and were found to be insignificant. B) mRNA was measured by real-time PCR after single or double knock-down
of LPCAT3 and LPCAT4 as described for panel A. Values are shown relative to the non-targeting control. Standard deviations and significances were
calculated as above (*** p ≤ 0.001, ** p ≤0.01). C) A431 cells were either transfected with non-targeting stealth siRNA or with stealth siRNA
sequence against LPCAT3 (siRNA3-2) or LPCAT4 (siRNA4-1) or combination (siRNA3-2;4-1). 48 h after transfection 100 μM oleate was added to
the medium to induce formation of LDs. 72 h after transfection cells were lysed and lipid droplets were purified using sucrose gradient and
subjected to a LPCAT activity assay. Values are normalized to the amount of the LD protein NSDHL as determined by western blotting. Standard
deviations and significances were calculated as above and were found to be insignificant. D) A431 cells were treated with stealth siRNA and
supplemented with oleate as described for panel C. 72 h after transfection cells were lysed and lysate was subjected to a LPCAT activity assay
using equal amounts of total protein. Standard deviations and significances were calculated from three experiments as above (*** p ≤ 0.001,
* p ≤0.05) compared to non-targeting control.
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Figure 6 The LPCAT1/2 fly ortholog CG32699 resembles human LPCAT1 and 2. A) Drosophila melanogaster S2 Schneider cells were transfected
with GFP-CG32699, which is the fly ortholog of mammalian LPCAT1 and LPCAT2. The growth medium was supplemented with 100 μM oleate. In the
merged image, LDs are shown in red and CG32699 in green. Lower panels show a higher magnification of the central region of the pictures in
the upper panels. Scalebar = 10 μm. Note the colocalization of GFP and LD540 signals. Resolution is limited due to the small size and round
shape of S2 cells. B) Female virgin flies of a tubulin-Gal4 containing fly strain were crossed with male flies of three different CG32699-specific
RNAi containing fly strains. L3 larvae were selected, fat bodies were isolated and representative DIC images of those fat bodies are shown for
wildtype (wt), white mutant (white) and the three RNAi strains 32382, 32924 and 104570. The amount of CG32699 mRNA was measured by
quantitative PCR. Scale bar = 10 μm. C + D) Bright field images as shown in panel B were quantified with ImageJ. Mean lipid droplet number
per frame and mean lipid droplet size is presented for 3 frames per condition of 4 different experiments. significances were calculated by
unpaired T-test analysis (*** p ≤ 0.001, ** p ≤0.01) compared to control. E) Female virgin flies of a tubulin-Gal4 containing fly strain were crossed
with male flies of 3 different CG32699-specific RNAi containing fly strains or white mutant (white). From each cross three L3 larvae were selected
and subjected to a LPCAT activity assay. Data were analyzed with Gel Pro Analyzer. Standard deviations and significances were calculated from three
experiments by unpaired T-test analysis (** p≤ 0.01, * p ≤0.05) compared to control (white).
Moessinger et al. BMC Cell Biology 2014, 15:43 Page 11 of 17
http://www.biomedcentral.com/1471-2121/15/43
Moessinger et al. BMC Cell Biology 2014, 15:43 Page 12 of 17
http://www.biomedcentral.com/1471-2121/15/43We showed that only LPCAT1 and LPCAT2, which
localize to the ER and LDs, are able to influence the LD
pool while the isoenzymes LPCAT3 and LPCAT4, which
localize to the ER, had no effect on the LD pool. Further-
more, we showed that interference with de-novo PC syn-
thesis pathway also influences the LD pool leading to a
similar phenotype as interference with the Land cycle, but
due to a different mechanism. While interference with
de-novo PC synthesis stimulates TAG synthesis and LD
loading, interference of the Lands cycle PC synthesis influ-
ences lipid packing by reduction of available or appropri-
ate surface. Our study identified an LPCAT1/2 ortholog in
Drosophila melanogaster with similar function in regulat-
ing the cellular LD pool, emphasizing the generality and
conservation of the underlying regulatory network. Our
work stresses the need to understand the differences and
importance of parallel synthesis pathways, isoenzymes and
localization of reactions in order to understand physio-
logical and pathological lipid storage.
Methods
Antibodies
Polyclonal rabbit antisera against the C-terminal peptide of
human LPCAT1 CNSDAGRKPVRKKLD, conjugated to
keyhole limpet hemocyanin, and against purified recom-
binant 6His-hLPCAT2310-545 were raised by Eurogentec
(Seraing, Belgium) and were affinity purified against the
respective antigen. Polyclonal goat anti-apoB was from
Merck Bioscience, monoclonal mouse anti-GAPDH anti-
body was from Novus Biological, HRP-coupled polyclonal
rabbit anti-goatIgG antibody from Invitrogen and HRP-
coupled polyclonal goat anti-rabbitIgG and anti-mouseIgG
from Dianova.
siRNA sequences
siRNA sequences against LPCAT1-4 were from Ambion
with the following order IDs:
LPCAT1
siRNA1#1: GGCCAGUAAGUACGGGAAAtt, ID 127470;
siRNA1#2: CCUUCAGCUCCGUUUCAAUtt, ID 127471;
siRNA1#3: GGACCUGCCUAAUUACCUUtt, ID 127469
LPCAT2
siRNA2#1: GGUAGAAGUUGAGUUUAUGtt, ID 25681;
siRNA2#2: GCAUGAAGAGAGUACCUCAtt, ID
140447,
against LPCAT3, stealth siRNA (Invitrogen) were used
as follows
siRNA3-1: LPCAT3 HSS115480, siRNA3-2: LPCAT3
HSS115481
against LPCAT4, stealth siRNA (Invitrogen) were used
as follows
siRNA4-1: LPCAT4 HSS137850, siRNA4-2: LPCAT4
HSS177724against CT1alpha, stealth siRNA (Invitrogen) were used
as follows
siRNA1: PCYT1A HSS107689, siRNA2: PCYT1A
HSS107690, siRNA3: PCYT1A HSS107691.
Drosophila strains
Control strains Oregon-R and w1118 were from Bloom-
ington Stock Center, the Gal4 driver strain tubulin-Gal4/
TM3 was a gift of the Eaton Lab at MPI-CBG. UAS-
CG32699RNAi strains (v32382, v32924 and v104570)
were obtained from the Vienna Drosophila RNAi Center.
Kits, reagents and chemicals
QiaShredder and RNeasy Mini Prep Kit was from Qiagen,
human apoB ELISAPRO was from Mabtech (Nacka Strand,
Sweden), RNase-free DNase was from Roche, reverse
transcriptase and RNasin were from Promega, real-time
PCR Lightcycler Mix and universal probes were from
Roche, primers were synthesized by Biospring, Interferin
was from Peqlab, [3H]oleate was from Hartmann Analytic,
the dyes 4′,6-Diamidino-2-phenylindol (DAPI) was from
Sigma-Aldrich and LD540 was synthesized as described in
Spandl et al. [73].
Cell culture
A431 cells were maintained in Dulbecco? s Modified Eagle? s
Medium (DMEM, Gibco 31966) supplemented with 10%
fetal calf serum (FCS), HuH7 cells in RPMI (Gibco 31870)
supplemented with 10 mM HEPES, 0.1 mM non-essential
amino acids, 2 mM L-Glutamine and 10% FCS. Cells were
grown at 37°C and 5% CO2.
Unless specifically indicated, media were not supple-
mented with additional fatty acid.
Drosophila Schneider 2 (S2) cells
Schneider 2 (S2) cells were cultured in Schneider medium
(PAN-Biotech) supplemented with 10% FCS. Cells were
grown in incubator at 28°C. Transfection of S2 cells The
fly gene CG32699 was cloned into a UAS-EGFP (kindly
provided by Bernard Fuss) containing plasmid by using
Xho1 and XbaI restriction enzymes, yielding a C-terminal
eGFP tagged CG32699 protein. Expression was induced
by cotransfection with pMT-Gal4, which is induced by
CuSO4. Cells were transfected in serum-free S2 medium
and Cellfectin (Invitrogen) with 2 μg of each plasmid
according to the manufacturers instructions. After 6 h
serum-containing S2 medium was added. About 24 h
after transfection the medium was replaced by serum-
containing S2 medium with 500 μM CuSO4. Cells were
processed for immunofluorescence after 24 h.
siRNA transfection
For transfection with siRNA, cells were seeded in 24-
well dishes at 5000 cells per well or 800000 per 15 cm
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siRNA using Interferin or Lipofectamine® 2000 (for
stealth siRNA) according to the manufacturers instruc-
tions. After 48 h or 72 h cells were subjected to im-
munofluorescence, lipid analysis, RNA isolation or SDS-
Page/Western blotting.
Fluorescence microscopy
Cells were grown on glass coverslips and transfected
with siRNA as indicated. After 48 h or 72 h, cells were
fixed with 3% (w/v) of paraformaldehyde in PBS for
30 min, washed with PBS and stained with DAPI and
Bodipy 493/503 or LD540 in PBS, followed by three
washes in PBS. After rinsing in water, coverslips were
mounted in Mowiol 4-88 containing 2.5% 1,4-diazabicy-
clo[2.2.2]octane. Images were acquired with a Zeiss LSM
510 confocal microscope equipped with a 100× NA 1.3
oil objective using laser excitation at 364 and 488 nm or
a ZEISS Axio Observer.Z1 with a 63× NA 1.2 objective.
Quantification of fluorescent images
Quantification was done with ImageJ particle analysis of
the LD detecting channel. The threshold was set to omit
the background, circularity adjusted to omit clusters and
particle detection only at a size between 0,02 and
20 μm2. The number of particles was normalized to the
total fluorescent area detected in the frame LD staining
channel.
Purification of lipid droplets and LPCAT activity assay
Cells were grown in 15 cm dishes and were supple-
mented with 100 μM oleate 24 h before lipid droplet iso-
lation. Cells were washed and scraped in ice-cold
disruption buffer (20 mM Hepes/NaOH, pH 7.4, 0.25 M
sucrose, Roche Complete protease inhibitors) and ho-
mogenized using the EMBL cell-cracker (HGM) with 12
strokes using a maximum clearance of 18 μm. The lysate
was centrifuged at 1000 g for 10 min and post-nuclear
supernatant (PNS) was adjusted to 1.1 M sucrose. Two
ml of adjusted PNS were overlaid with 10 ml of ice-cold
disruption buffer in centrifuge tube. The gradients were
centrifuged using a Beckman L-60 ultracentrifuge with
the SW41 rotor at 110000 g at 4°C for 3 h. 1.5 ml of
lipid droplet fraction was collected from the top. For
LPCAT activity assay 10 μl of lysate (adjusted according
to protein concentration measured with Bradford re-
agent) or 150 μl of lipid droplet fraction (adjusted ac-
cording to relative amount of NSDHL measured by WB
analysis) were mixed with 100 or 150 μl of assay buffer
(200 mM Tris/HCl pH 7.5, 10 mM MgCl2, 2 mg/ml fatty
acid free BSA) supplemented with 100 μM propargyl
LPC (final concentration) and 20 μM oleoyl-CoA (final
concentration), and subsequently incubated for 10 min
at 30°C. Reaction was stopped by adding 800 μl ofchloroform/methanol, 1:3, and 400 - 600 μM of 1%
acetic acid in water. The phases were separated by cen-
trifugation at 14000 × g for 30 s. The chloroform phase
was collected for the click reaction, which was per-
formed as described below.
Lipid extraction from 24 well plate
Cells were washed twice with 1% delipidated BSA in PBS
and once with only PBS. Lipids were extracted directly
from the dish using first 400 μl of chloroform/methanol,
1:5 followed by 400 μl of chloroform/methanol 1/1.
After addition of 600 μl of water, phases were separated
by centrifugation. The chloroform phase was collected
for Click reaction, which was performed as described
below.
Lipid analysis by mass spectrometry
Cell were scraped into 155 mM NH4HCO3 and were
mixed with 20 μl internal lipid standard mixture provid-
ing a spike of 57 pmol PE 17:0/17:0, 47 pmol PC 18:3/
18:3, 47 pmol SM 17:0, 37 pmol DAG 17:0/17:0, 37
pmol TAG 17:1/17:1/17:1 and 57 pmol CE 17:0. Samples
were extracted with 990 μl chloroform/methanol (15:1)
for 120 min at 4°C [74]. The apolar organic phase was
isolated and evaporated. Lipid extracts were dissolved in
200 μl of 7.5 mM ammonium acetate in chloroform/
methanol/2-propanol (1:2:4) and subjected to quantita-
tive lipid analysis in positive ion mode on a QSTAR
Pulsar-i instrument (MDS Analytical Technologies) or a
LTQ Orbitrap mass spectrometer (Thermo Fisher Scientific)
equipped with a TriVersa NanoMate nanoflow ion source
(Advion Biosciences, Inc., Ithaca, NJ) [74-77].
Real-time PCR
RNA was extracted into 30 μl nuclease-free water from a
24-well according to manufactures description with the
RNeasy Mini Prep Kit (Qiagen). RNA (11 μl) was tran-
scribed to cDNA using reverse Transcriptase. The cDNA
was diluted 1:5 with nuclease-free water and 4 μl were
used for real-time PCR. Real-time PCR was performed on
a LightCycler® 480II from Roche using the universal probe
system from Roche. For LPCAT3 Sonde8, for LPCAT4
Sonde48, for CTalpha Sonde 72 and as reference gene
GAPDH Sonde60 were used. Sequences of the RT-PCR
Primer: LPCAT3 Primer1: GGGCTACGTCTCCTTCG
ATT, Primer2: ATTTGTCCCACGTGAAGAGG; LPCAT4
Primer1: GCGTTGGAACCACAGCTC, Primer2: ACATA
GCCAGCGGACAGC; CTalpha Primer1: GATGAGGTG
GTGAGGAATGC, Primer2: TGCCAGCAGATGAATA
AGGA; GAPDH Primer1: AGCCACATCGCTCAGACAC;
Primer2: GCCCAATACGACCAAATCC.
Real-time PCR analysis of Drosophila strains was per-
formed as described in [57]. RpL32 (rp49) Primer 1:
GCTAAGCTGTCGCACAAATG, Primer2:GTTCGATC




Analysis of Drosophila melanogaster strains
Four to six L3 larvae were collected and dissected in
PBS on ice. Fat bodies were transferred in PBS to object
slides on ice and covered with coverslips. Microscopy
was performed with a 63× NA 1.2 water objective using
differential interference contrast brightfield. The images
were processed and analysed with ImageJ. Processing of
the image includes sharpening, despeckle and contrast
enhancement. Structures were detect with the functions
Find Edges, Make Binary, Morphology Tool (circle 5.00,
close), Binary erode, Set Threshold, and analyse particle
(circle, micron2, 0-infinity, exclude edges). The number
and size of particles detected were selected as output
data. The analysis is based on 4 independent experi-
ments and 3 pictures per condition per experiment. The
significance was calculated by unpaired students T-Test
to wildtype fly larvae.
Acyltransferase assay in L3 larvae using click chemistry
We applied the assay procedure as recently described
[78], based on quantitative click-analysis of lipid metab-
olism [79]. L3 larvae were homogenized with a pestle
and 60 μl of disruption buffer (20 mM HEPES/NaOH,
pH 7.4, 0.25 M sucrose) was added. Then it was mixed
with 40 μl of assay buffer (150 mM Tris/HCl, pH 7.5,
7.5 mM MgCl2, 1.5 mg/ml fatty acid-free bovine serum
albumin (BSA), 250 μM oleoyl-CoA (Sigma), 250 μM
propargyl LPC) and 10 min incubation at 30°C followed.
Reaction was stopped by adding 500 µl of chloroform/
methanol, 1:3, and 500 µl of 1% acetic acid in water. The
phases were separated by centrifugation at 1900 × g for
5 min. The upper phase was removed and 70 µl of the
lower chloroform phase was taken for Click reaction.
Chloroform was evaporated, then 7 μl of chloroform
and 30 μl of reaction mixture (2.3 mM Cu(I)BF4,
0.08 mM hydroxyazidocoumarin in ethanol/aceto-
nitrile, 3.4:1) was added and 2.5 h incubation at 42°C
followed. Reaction mixture was separated by TLC,
first in CHCl3/MeOH/H2O/Acetic acid, 65:25:4:1 for
40 min, then in hexane/ethyl acetate, 1:1 for 30 min.
The plate was dried, briefly immersed into 4% diiso-
propylethylamine in hexane, dried again and exposed
to 420 nm light. Emission signal was detected with
CCD camera and then quantified.
ApoB secretion assays
HuH7 cells were plated in 24well plates (5000 cells per
well) 16 h prior transfection. Cells were transfected with
siRNAs (control siRNA scrambled#5 or #6 and siRNA
against LPCAT1 siRNA1#1 and siRNA1#3) using thetransfection reagent Interferin according to manufac-
tures instructions. Transfections were performed in
100 μl OPTI-MEM and 500 μl serum-free supplemented
RPMI medium. In case of radioactive quantification of
lipid release, 1 μCi [3H]oleate was added to the medium
per 24-well for 24 h. Then, remaining radioactivity was
removed and cells were grown in 200 μl serum-free sup-
plemented RPMI for further 48 h. In case of apoB deter-
mination by apoB ELISA, siRNAs were removed after
24 h and cells were grown for further 48 h in 200 μl
serum-free RPMI. Supernatants were collected 72 h
after transfection and corresponding cells were either
scraped in 50 μl Lämmli buffer (apoB measurement by
Western blotting) or lipids were extracted (measure-
ment of radioactive labeled lipid release) or protein con-
tent was measured with a protein detection assay from
Bio-Rad (apoB measurement by ELISA). Supernatants
were either mixed with Lämmli buffer (apoB measure-
ment by Western blotting) or lipids were extracted
(measurement of radioactive labeled lipid release) or
they were subjected to human apoB ELISAPRO from
Mabtech (Nacka Strand, Sweden). For quantification of
apoB release by Western blotting, supernatant (40 μl)
and cell lysate (15 μl) were subjected to SDS-PAGE and
Western blotting and analyzed for apoB and LPCAT1
and GAPDH, respectively, and the amounts for apoB
and LPCAT1 were normalized to GAPDH and com-
pared to control. For characterization and quantifica-
tion of released radiolabeled lipids, the extracted lipids
were separated by thin layer chromatography or quan-
tifed by scintillation counting. For quantifaction of apoB
release by ELISA the amount of apoB released was nor-
malized to the total protein content and compared to
control.
Additional file
Additional file 1: Figure S1. Density profile of apolipoprotein B
containing lipoprotein particles secreted from HuH7 cells. Supernatant of
HuH7 cells was separated by density gradient centrifugation based on
sodium chloride and sodium bromide containing medium and the
different density fractions were blotted for apoB protein.
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